STOCK TITAN

Xilio Therapeutics: ADAR1 reports 9.3% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Xilio Therapeutics, Inc. (XLO) is the issuer for which ADAR1 Capital Management, LLC, an investment adviser, and its sole manager, Daniel Schneeberger, report beneficial ownership of 381,000 shares. Both report shared voting and dispositive power over the same shares, which are underlying pre-funded and common warrants held directly by private investment funds managed by ADAR1; the securities may be deemed indirectly beneficially owned by the reporting persons. The reported amount is 9.3% of the class, based on 3,702,072 shares outstanding as of September 30, 2025. The reported share counts account for the 1-for-14 reverse split that occurred March 13, 2026.

Beneficially owned underlying shares 381,000 shares Reported by ADAR1 Capital Management, LLC and Daniel Schneeberger; the same shares underlie warrants.
Ownership percentage 9.3% Percentage of the class reported by each reporting person.
Common shares outstanding 3,702,072 shares As of September 30, 2025; the reported count accounts for the 1-for-14 reverse split on March 13, 2026.
pre-funded warrants financial
"shares of Common Stock underlying pre-funded warrants and common warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shared voting power regulatory
"Shared Voting Power 381,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 381,000.00"
control person regulatory
"filing this Schedule as a control person"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.
investment adviser regulatory
"an investment adviser as described"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many XLO shares do ADAR1 and Daniel Schneeberger report as beneficially owned?

ADAR1 Capital Management, LLC and Daniel Schneeberger each report shared voting and dispositive power over 381,000 shares, or 9.3% of the class as reported. The shares underlie pre-funded and common warrants held directly by private investment funds managed by ADAR1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





98422T209

(CUSIP Number)
09/30/2025

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 381,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Xilio Therapeutics, Inc. (the "Issuer") underlying pre-funded warrants and common warrants owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by ADAR1. Based on 3,702,072 shares of Common Stock of the Issuer outstanding as of September 30, 2025, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 13, 2025. The number of shares outstanding and the number of shares held by ADAR1 are calculated with accounting for the 1-for-14 reverse stock split that occurred on March 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 381,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Xilio Therapeutics, Inc. (the "Issuer") underlying pre-funded warrants and common warrants owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. Based on 3,702,072 shares of Common Stock of the Issuer outstanding as of September 30, 2025, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 13, 2025. The number of shares outstanding and the number of shares held by ADAR1 are calculated with accounting for the 1-for-14 reverse stock split that occurred on March 13, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026

Keep reading